Cargando…
Screening for Hepatitis C Virus: How Universal Is Universal?
In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive on...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376340/ https://www.ncbi.nlm.nih.gov/pubmed/32712026 http://dx.doi.org/10.1016/j.clinthera.2020.06.012 |
_version_ | 1783562025257926656 |
---|---|
author | Jhaveri, Ravi |
author_facet | Jhaveri, Ravi |
author_sort | Jhaveri, Ravi |
collection | PubMed |
description | In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive one-time hepatitis C virus antibody screening in any health care setting. Although the recommendation is dubbed “universal,” this commentary reviews the details of the recommendations and discusses the high-risk populations not entirely captured with these changes. |
format | Online Article Text |
id | pubmed-7376340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73763402020-07-23 Screening for Hepatitis C Virus: How Universal Is Universal? Jhaveri, Ravi Clin Ther Commentary In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive one-time hepatitis C virus antibody screening in any health care setting. Although the recommendation is dubbed “universal,” this commentary reviews the details of the recommendations and discusses the high-risk populations not entirely captured with these changes. Elsevier Inc. 2020-08 2020-07-23 /pmc/articles/PMC7376340/ /pubmed/32712026 http://dx.doi.org/10.1016/j.clinthera.2020.06.012 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Commentary Jhaveri, Ravi Screening for Hepatitis C Virus: How Universal Is Universal? |
title | Screening for Hepatitis C Virus: How Universal Is Universal? |
title_full | Screening for Hepatitis C Virus: How Universal Is Universal? |
title_fullStr | Screening for Hepatitis C Virus: How Universal Is Universal? |
title_full_unstemmed | Screening for Hepatitis C Virus: How Universal Is Universal? |
title_short | Screening for Hepatitis C Virus: How Universal Is Universal? |
title_sort | screening for hepatitis c virus: how universal is universal? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376340/ https://www.ncbi.nlm.nih.gov/pubmed/32712026 http://dx.doi.org/10.1016/j.clinthera.2020.06.012 |
work_keys_str_mv | AT jhaveriravi screeningforhepatitiscvirushowuniversalisuniversal |